The effects of genetic polymorphisms in drug-metabolizing enzymes (eg, CYP2C9* 3) on
drug clearance have been well characterized but much less is known about whether these …

Cytochrome P-450 (CYP) 2C9 CYP2C9 is a polymorphically expressed enzyme responsible
for the metabolism of several clinically important drugs, some with a low therapeutic index …

Background Genetic variability in the cytochrome P450 CYP2C9 constitutes an important
predictor for efficacy and safety of various commonly prescribed drugs, including coumarin …

Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …

CYP2D6 is of great importance for the metabolism of clinically used drugs and about 20–
25% of those are metabolised by this enzyme. In addition, the enzyme utilises …

It has been recognized extensively that studies of pharmacogenetics provide massive
examples of causal relationship between genotypes and drug effectiveness to account for …

Genetic variation has a significant impact on an individual's metabolism and response to a
wide range of medications. The cytochrome P450 family of enzymes are key determinants in …

Pharmacogenetics dates back more than 2,000 years to observations by Pythagoras,
however it was not until the 1950s when some enzyme polymorphisms (eg, N …

Pharmacogenetics deals with clinically significant hereditary variations in the response to
drugs due to altered drug disposition and abnormal drug action in affected persons. In …

Prior knowledge of allele frequencies of cytochrome P450 polymorphisms in a population is
crucial for the revision and optimization of existing medication choices and doses. In the …